JP2013511553A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511553A5
JP2013511553A5 JP2012540141A JP2012540141A JP2013511553A5 JP 2013511553 A5 JP2013511553 A5 JP 2013511553A5 JP 2012540141 A JP2012540141 A JP 2012540141A JP 2012540141 A JP2012540141 A JP 2012540141A JP 2013511553 A5 JP2013511553 A5 JP 2013511553A5
Authority
JP
Japan
Prior art keywords
alkyl
cyclic peptide
xaa
aryl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012540141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511553A (ja
JP5999702B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057699 external-priority patent/WO2011063366A1/en
Publication of JP2013511553A publication Critical patent/JP2013511553A/ja
Publication of JP2013511553A5 publication Critical patent/JP2013511553A5/ja
Application granted granted Critical
Publication of JP5999702B2 publication Critical patent/JP5999702B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012540141A 2009-11-23 2010-11-23 メラノコルチン−1受容体特異的環状ペプチド Active JP5999702B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26349009P 2009-11-23 2009-11-23
US61/263,490 2009-11-23
PCT/US2010/057699 WO2011063366A1 (en) 2009-11-23 2010-11-23 Melanocortin-1 receptor-specific cyclic peptides

Publications (3)

Publication Number Publication Date
JP2013511553A JP2013511553A (ja) 2013-04-04
JP2013511553A5 true JP2013511553A5 (enExample) 2014-01-16
JP5999702B2 JP5999702B2 (ja) 2016-09-28

Family

ID=44060071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540141A Active JP5999702B2 (ja) 2009-11-23 2010-11-23 メラノコルチン−1受容体特異的環状ペプチド

Country Status (14)

Country Link
US (6) US8492517B2 (enExample)
EP (1) EP2504352B1 (enExample)
JP (1) JP5999702B2 (enExample)
KR (1) KR101921761B1 (enExample)
CN (1) CN102725305B (enExample)
AU (2) AU2010321738B2 (enExample)
BR (1) BR112012011787B1 (enExample)
CA (1) CA2781402C (enExample)
EA (1) EA021897B1 (enExample)
IL (1) IL219947A (enExample)
MX (1) MX2012005862A (enExample)
NZ (1) NZ599774A (enExample)
WO (1) WO2011063366A1 (enExample)
ZA (1) ZA201203330B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201290295A1 (ru) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
AU2010321738B2 (en) * 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
EP2814501A4 (en) 2012-03-13 2016-03-02 Tensive Controls Inc MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
WO2014081846A2 (en) * 2012-11-21 2014-05-30 University Of Cincinnati Pharmaceutical compositions and therapeutic methods of use comprising selective agonists of melanocortin 1 receptor
WO2015063099A1 (en) 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in the treatment of hailey-hailey disease
WO2015063102A1 (en) 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in bullous disease
WO2015067503A1 (en) 2013-11-07 2015-05-14 Clinuvel Ag Alpha-msh analogues for use in the treatment of psoriasis
US20160354437A1 (en) * 2014-02-13 2016-12-08 Northwestern University Compositions and methods for modulation of immune response
WO2016066702A1 (en) 2014-10-28 2016-05-06 Clinuvel Ag Inflammatory disease
US20170304406A1 (en) 2014-10-28 2017-10-26 Clinuvel Ag New indication for alpha-msh analogues
RS61853B1 (sr) 2014-10-29 2021-06-30 Bicyclerd Ltd Biciklični peptidni ligandi specifični za mt1-mmp
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US10729669B2 (en) 2015-07-28 2020-08-04 University Of Iowa Research Foundation Compositions and methods for treating cancer
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
JP7039814B2 (ja) * 2016-10-04 2022-03-23 ディーエスエム アイピー アセッツ ビー.ブイ. メラノコルチン-1-受容体アゴニスト
EP3573645B1 (en) * 2017-02-01 2024-03-13 Vallaurix Mc S.A.R.L. Alpha-msh analogues used in the treatment of xeroderma pigmentosum
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
KR20200128518A (ko) 2018-02-23 2020-11-13 바이사이클티엑스 리미티드 다량체성 비사이클릭 펩타이드 리간드
MX2020009900A (es) * 2018-03-23 2021-01-08 Palatin Technologies Inc Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal.
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
KR20230074119A (ko) 2020-08-03 2023-05-26 바이사이클티엑스 리미티드 펩타이드 기반 링커
WO2023091689A1 (en) 2021-11-19 2023-05-25 University Of Iowa Research Foundation Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE109793T1 (de) 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
DE69429768T2 (de) 1993-04-05 2002-09-19 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
CA2158425C (en) 1995-09-15 2003-01-28 Mac E. Hadley Diagnostic and treatment of erectile dysfunction
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
EP0946595A2 (en) 1996-12-17 1999-10-06 Quadrant Holdings Cambridge Limited Melanocortins
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
CA2357036A1 (en) 1998-12-23 2000-07-06 Merck & Co., Inc. Dna molecules encoding splice variants of the human melanocortin 1 receptor protein
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
ATE393783T1 (de) 1999-03-29 2008-05-15 Procter & Gamble Melanocortinrezeptor-liganden
PL352763A1 (en) * 1999-06-25 2003-09-08 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Somatostatin agonists
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US7049398B1 (en) 1999-08-12 2006-05-23 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
AU2001229491A1 (en) * 2000-01-18 2001-07-31 Merck And Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
WO2001085930A2 (en) 2000-05-09 2001-11-15 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
WO2002018437A2 (en) 2000-08-30 2002-03-07 F. Hoffmann-La Roche Ag Cyclic peptides having melanocortin-4 receptor agonist activity
PL362003A1 (en) 2000-09-27 2004-10-18 The Procter & Gamble Company Melanocortin receptor ligands
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
AU2002322466B2 (en) 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
EP1409521A2 (en) 2001-07-12 2004-04-21 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US20030186249A1 (en) 2002-04-01 2003-10-02 Zairen Sun Human TARPP genes and polypeptides
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
AU2003248888A1 (en) 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
US20060122121A1 (en) 2002-11-14 2006-06-08 Lipton James M Modified alpha-MSH peptides and derivatives thereof
EP1625158A2 (en) * 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
MXPA05011830A (es) * 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
WO2005000338A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
EP1644023A2 (en) 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
US20050026948A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
JP4754487B2 (ja) 2003-08-20 2011-08-24 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
CN101497654A (zh) 2003-09-30 2009-08-05 诺沃挪第克公司 黑皮素受体激动剂
WO2005047251A1 (en) 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Melanocortin receptor agonists
DK1689349T3 (da) 2003-11-24 2013-12-02 Clinuvel Pharmaceuticals Ltd Fremgangsmåde til induktion af melanogenese i mennesker med variante MC1R-alleler
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
US8193310B2 (en) * 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
JP2007530674A (ja) 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−4受容体(mc4r)アゴニストペプチドの使用
CN1563076A (zh) 2004-04-02 2005-01-12 西南生物工程产业化中试基地有限公司 一种用于治疗性功能障碍的α-MSH类似物及制备方法
WO2005118573A1 (en) 2004-05-28 2005-12-15 Smithkline Beecham Corporation Novel diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
US9345911B2 (en) 2004-08-04 2016-05-24 Clinuvel Pharmaceuticals Limited Methods of inducing melanogenesis in a subject
TW200626611A (en) 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
JP5449673B2 (ja) 2004-10-08 2014-03-19 クリヌベール、ファーマスーティカルズ、リミテッド 対象者におけるメラニン形成を誘導するための組成物および方法
BRPI0518411A2 (pt) 2004-10-25 2008-11-18 Centocor Inc mimeticorpos que se ligam a receptor de melanocortina, composiÇÕes, mÉtodos e usos
EP1809665A2 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
CN101052650A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
EP1809666A2 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Peptides for use in the treating obesity
WO2006048451A1 (en) 2004-11-04 2006-05-11 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2006060873A1 (en) 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
EP1863841A1 (en) 2005-03-17 2007-12-12 Novo Nordisk A/S Compounds for use in the treatment of obesity
WO2006129317A1 (en) 2005-05-31 2006-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem BACKBONE CYCLIZED MELANOCORTIN STIMULATING HORMONE (α S ) ANALOGS
AU2006269321A1 (en) 2005-07-08 2007-01-18 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
RU2439079C2 (ru) 2005-07-08 2012-01-10 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик С.А.С. Лиганды рецепторов меланокортинов
CN1709906A (zh) 2005-07-15 2005-12-21 中国科学技术大学 α-促黑激素的环状类似肽及其应用
CN101222942A (zh) 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽
US8466104B2 (en) 2005-08-26 2013-06-18 Abbvie Inc. Therapeutically active alpha MSH analogues
EP1957096A4 (en) 2005-08-29 2012-03-21 Palatin Technologies Inc CYCLIC PEPTIDE INSULATION BY SPRAY DRYING
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
US8114844B2 (en) * 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
AU2007291943B2 (en) * 2006-08-28 2013-11-14 Clinuvel Pharmaceuticals Limited Method for reducing incidence or rate of development of skin cancers and related conditions
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
US7879894B2 (en) * 2006-11-28 2011-02-01 Warsaw Orthopedic, Inc. Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome
JP2010517943A (ja) 2007-01-18 2010-05-27 ノボ・ノルデイスク・エー/エス 肥満の治療に使用される新規ペプチド
JP2010516652A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー/エス 肥満の治療に使用される新規ペプチド
EP2106407A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
WO2008087188A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
KR101120227B1 (ko) 2007-03-16 2012-03-20 화이자 리미티드 5-[3-(3-하이드록시페녹시)아제티딘-1-일]-5-메틸-2,2-다이페닐-헥산아마이드의 염산염
FR2914646A1 (fr) 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
KR20100063116A (ko) 2007-09-12 2010-06-10 글락소 그룹 리미티드 치료제들의 복합제
CA2952095C (en) 2007-11-05 2020-02-18 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
AR072072A1 (es) 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
JP5628796B2 (ja) * 2008-06-09 2014-11-19 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. 性的不能の治療用のメラノコルチンレセプタ特異的ペプチド
WO2010144344A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
EA201290295A1 (ru) * 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
AU2010321738B2 (en) * 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides

Similar Documents

Publication Publication Date Title
JP2013511553A5 (enExample)
JP2013511554A5 (enExample)
JP2012529433A5 (enExample)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
JP2025122030A (ja) EphA2に特異的な二環式ペプチドリガンド
Biron et al. Convenient synthesis of N-methylamino acids compatible with Fmoc solid-phase peptide synthesis
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
US20240083945A1 (en) Anti-infective bicyclic peptide ligands
JP2013533864A5 (enExample)
JP2014520120A5 (enExample)
RU2014148530A (ru) Производные дипептида лизин-глутаминовая кислота
JP2017061474A5 (enExample)
MY161450A (en) Double-acylated glp-1 derivatives
JP2014224126A5 (enExample)
BR112012011787A2 (pt) peptídeo cíclico, composição farmacêutica, método para tratamento de uma doença, indicação, condição ou síndrome mediada por receptor de melanocortina em um mamífero humano ou não humano e método para tratamento de uma condição responsiva a mudanças na função de receptor de melanocortina em mamífero humano ou não humano
IL180727A (en) Antifungal peptides containing motif including arginine and / or lysine
JP2013500990A5 (enExample)
ATE482978T1 (de) Mimetische cd4-peptide und ihre verwendungen
NZ566020A (en) Prion-specific peptoid reagents
JP2016516734A5 (enExample)
TW201922769A (zh) 胜肽化合物之製造方法
JP6468562B2 (ja) プロテアソーム阻害性化合物
CA3206846A1 (en) Anti-infective bicyclic peptide ligands
DE602006010740D1 (de) Rekombinante gelatinepartikel für die zelladhäsion
Schlitzer et al. Non-thiol farnesyltransferase inhibitors: structure–activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors